Joyani Das, PhD, earned her doctoral degree in pharmacology from the Birla Institute of Technology in Mesra, India, and brings over six years of experience in medical research, education, and health communication. She works as a medical writer, creating evidence-based health content for a broad audience. Prior to this, she worked as a health writer at MomJunction, specializing in health and wellness topics related to women and children. She also served as an associate professor, contributing to academic research and mentoring students in pharmacological sciences. Her areas of expertise include medical writing and drug information.
Recent WebMD content from Joyani Das, PhD
- Casgevy: FDA Expands One-Time Gene Therapy for Sickle Cell Disease and Beta Thalassemia to Children as Young as 2 Years
- Tregzi: FDA Approves Donor Immune Cell Therapy to Lower the Risk of Serious Problems in Adults With Blood Cancer
- Zoryve Cream: FDA Expands Approval for Once-Daily Topical for Plaque Psoriasis in Children Aged 2 or Older
- Skyrizi: FDA Approves Pediatric Expansion of IL‑23 Inhibitor for Moderate-to-Severe Plaque Psoriasis and Active Psoriatic Arthritis
- Lumvoa: FDA Approves New Intravenous Treatment for Both Active and Chronic Thyroid Eye Disease
- Ibrance: FDA Approves Oral Targeted Therapy With Anti‑HER2 and Endocrine Therapy for HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
- Tecelra: FDA Expands T-Cell Therapy to Include Patients as Young as 12 Years Old With Advanced Synovial Sarcoma
- Welireg With Keytruda or Keytruda Qlex: FDA Approves Adjuvant Therapy Combination for Certain Adults With Clear Cell Renal Cell Carcinoma After Surgery
- FDA Approves Truqap as the First Targeted Therapy for PTEN-Deficient Metastatic Prostate Cancer
- FDA Approves Tzield to Slow the Decline of Natural Insulin Production in People 8-17 Years Old With Newly Diagnosed Stage 3 Type 1 Diabetes
- Ebglyss: FDA Approves Once-Every-8-Week Maintenance Injection Option for Moderate to Severe Eczema in Adults and Children Ages 12 Years and Older
- Parsol Shield: FDA Approves New Sunscreen Active Ingredient for Broad UV Protection
- Cavhanza (Nilotinib): FDA Approves Orally Disintegrating Tablet for Adults With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- Zaynich: FDA Approves New IV Antibiotic for Complicated Urinary Tract Infections in Adults
- Xocova: FDA Approves First Oral Post-Exposure Prophylaxis to Help Prevent COVID-19 in Adults and Adolescents 12 and Older
- FDA Expands Tremfya Label to Highlight Protection Against Joint Damage in Psoriatic Arthritis
- Imfinzi: FDA Approves Immunotherapy Plus BCG Combination for High-Risk Early Non-Muscle-Invasive Bladder Cancer
- FDA Clears Once-Daily Linzess Capsule for Functional Constipation in Children Ages 2 Years and Older
- Datroway: FDA Approves Antibody-Drug Conjugate Injection for Advanced Triple-Negative Breast Cancer
- Fasenra: FDA Approves Under-the-Skin Shot to Help Reduce Flares in Hypereosinophilic Syndrome
- Tecentriq and Tecentriq Hybreza: FDA Approves First ctDNA‑Guided Adjuvant Immunotherapies to Target Residual Muscle‑Invasive Bladder Cancer After Surgery
- Enhertu: FDA Clears New Pre- and Post-Surgery Uses in HER2-Positive Early Breast Cancer
- Beqalzi: FDA Approves New Oral BCL-2 Blocker for Relapsed or Refractory Mantle Cell Lymphoma
- Inqovi: FDA Approves First All‑Oral Regimen for Certain Patients With Newly Diagnosed Acute Myeloid Leukemia
- Bizengri: FDA Approves Second-Line Intravenous Treatment for Adults With NRG1 Fusion-Positive, Advanced, Surgically Unresectable, Metastatic Bile Duct Cancer
- Vyvgart: FDA Expands Label to Include All Adults With Generalized Myasthenia Gravis
- Ocrevus: FDA Approves Intravenous Targeted Therapy for Children Aged 10 Years or Older With Relapsing-Remitting Multiple Sclerosis
- Asceniv: FDA Extends Use of Intravenous Immunoglobulin for Primary Humoral Immunodeficiency in Children 2 and Older
- Breztri Aerosphere: FDA Approves Single-Inhaler Triple Therapy for Maintenance Control of Asthma in Patients Ages 12 Years or Older
- Caplyta (Lumateperone): FDA Updates Labeling for Once-Daily Antipsychotic to Help Prevent Relapse in Patients With Schizophrenia
